nach oben

Breast Cancer Research and Treatment

Erschienen in:

02.06.2017 | Clinical trial

Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657)

verfasst von: Neelima Vidula, Christina Yau, Jiali Li, Laura J. Esserman, Hope S. Rugo

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) axis may contribute to the development of bone metastases (BM). We studied gene expression in this pathway in primary breast cancer (BC) to determine correlations with clinical characteristics and outcomes in the neoadjuvant I-SPY1 study.

Methods

We evaluated RANK/RANKL/OPG expression using expression microarrays in I-SPY1 (n = 149). Associations with clinical features were determined using t test and ANOVA. Associations between biomarker high versus low groups (dichotomized at an optimal cutpoint) and recurrence-free survival (RFS) were evaluated using the log-rank test and in a multivariate Cox proportional hazard model. A pooled external neoadjuvant cohort with gene expression data (GSE25066) (Hatzis et al. in JAMA 305(18):1873–1881, 30) (n = 425) was used for validation. Associations with site-specific relapse were evaluated using the t-test and multivariate logistic regression adjusting for hormone receptor (HR) status.

Results

RANK was significantly higher in HR negative versus HR positive (p = 0.027), in basal versus non-basal disease (p = 0.004), and in those achieving pathologic complete response (p = 0.038); the associations with HR negative and basal BC were also significant in GSE25066. In both datasets, higher RANK associated with significantly worse RFS (I-SPY1: p = 0.045, GSE25066: p = 0.044). However, this association did not remain significant after adjusting for HR status. In I-SPY1 patients with recurrence, higher RANK correlated with BM versus non-BM (p = 0.045), even after adjusting for HR status (p = 0.035).

Conclusions

RANK is increased in HR negative and basal BC, and correlates with worse RFS and risk of BM. The RANK pathway is a potential therapeutic target in BC.

Nur mit Berechtigung zugänglich

National Cancer Institute. SEER Stat Fact Sheets: Breast Cancer. http://seer.cancer.gov/statfacts/html/breast.html. Accessed 26 Dec 2014

Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179–1183. doi:10.1093/jnci/djn233 CrossRefPubMed

van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536. doi:10.1038/415530a CrossRef

Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van’t Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N (2012) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 132(3):1049–1062. doi:10.1007/s10549-011-1895-2 CrossRefPubMed

Piccart M RE vtVL, Slaets L, Delaloge S, Viale G, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis P, Coudert B, Smilde T, Gil M, Thompson A, Rubio IT, Passalaqua R, Matos E, Nitz U, Delorenzi M, Thomas G, Goulioti T, Straehle C, Tryfonidis K, Bogaerts J, Cardoso F (2016) Primary analysis of the EORTC 10041/BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint^®) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. AACR SI-05

Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55(1):61–66CrossRefPubMedPubMedCentral

Shimamura T, Amizuka N, Li M, Freitas PH, White JH, Henderson JE, Shingaki S, Nakajima T, Ozawa H (2005) Histological observations on the microenvironment of osteolytic bone metastasis by breast carcinoma cell line. Biomed Res 26(4):159–172CrossRefPubMed

Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79(5–6):243–253CrossRefPubMed

Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390(6656):175–179. doi:10.1038/36593 CrossRefPubMed

10.

Kang JH, Ko HM, Moon JS, Yoo HI, Jung JY, Kim MS, Koh JT, Kim WJ, Kim SH (2014) Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis. J Dent Res 93(11):1116–1123. doi:10.1177/0022034514552677 CrossRefPubMedPubMedCentral

11.

Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Bravaccini S, Ricci R, Serra L, Amadori D (2011) The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. Oncology 80(3–4):225–231. doi:10.1159/000327585 CrossRefPubMed

12.

Dar A, Kollet O, Lapidot T (2006) Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol 34(8):967–975. doi:10.1016/j.exphem.2006.04.002 CrossRefPubMed

13.

Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102(39):13909–13914. doi:10.1073/pnas.0506517102 CrossRefPubMedPubMedCentral

14.

Dougall WC (2012) Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18(2):326–335. doi:10.1158/1078-0432.ccr-10-2507 CrossRefPubMed

15.

Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320):98–102. doi:10.1038/nature09387 CrossRefPubMedPubMedCentral

16.

Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320):103–107. doi:10.1038/nature09495 CrossRefPubMed

17.

Azim H, Azim HA Jr (2013) Targeting RANKL in breast cancer: bone metastasis and beyond. Expert Rev Anticancer Ther 13(2):195–201. doi:10.1586/era.12.177 CrossRefPubMed

18.

Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A, Guise TA, Costa L (2013) RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS ONE 8(5):e63153. doi:10.1371/journal.pone.0063153 CrossRefPubMedPubMedCentral

19.

Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D, Mukai J, Sakaguchi K, Satou T, Nishida S (2013) Activation of NF-kappaB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res 32:62. doi:10.1186/1756-9966-32-62 CrossRefPubMedPubMedCentral

20.

Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440(7084):692–696. doi:10.1038/nature04524 CrossRefPubMed

21.

Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470(7335):548–553. doi:10.1038/nature09707 CrossRefPubMedPubMedCentral

22.

Pellegrini P, Cordero A, Gallego MI, Dougall WC, Purificacion M, Pujana MA, Gonzalez-Suarez E (2013) Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells 31(9):1954–1965. doi:10.1002/stem.1454 CrossRefPubMed

23.

Labovsky V, Vallone VB, Martinez LM, Otaegui J, Chasseing NA (2012) Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines. Cancer Cell Int 12(1):29. doi:10.1186/1475-2867-12-29 CrossRefPubMedPubMedCentral

24.

Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A, Climent F, Soler MT, Munoz P, Vinals F, Tometsko M, Branstetter D, Dougall WC, Gonzalez-Suarez E (2012) RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 72(11):2879–2888. doi:10.1158/0008-5472.can-12-0044 CrossRefPubMed

25.

Park HS, Lee A, Chae BJ, Bae JS, Song BJ, Jung SS (2014) Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer. J Surg Oncol 110(7):807–812. doi:10.1002/jso.23737 CrossRefPubMed

26.

Pfitzner BM, Branstetter D, Loibl S, Denkert C, Lederer B, Schmitt WD, Dombrowski F, Werner M, Rudiger T, Dougall WC, von Minckwitz G (2014) RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat 145(2):307–315. doi:10.1007/s10549-014-2955-1 CrossRefPubMed

27.

Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G (2011) Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE 6(4):e19234. doi:10.1371/journal.pone.0019234 CrossRefPubMedPubMedCentral

28.

Owen S, Ye L, Sanders AJ, Mason MD, Jiang WG (2013) Expression profile of receptor activator of nuclear-kappaB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res 33(1):199–206PubMed

29.

Ruckhaeberle E, Mueller V, Schmidt M, Saenger N, Hanker L, Gaetje R et al (2012) P3-01-12: prognostic impact of RANK, RANKL, and OPG gene expression in ER positive primary breast cancer. Cancer Res 71(24 Supplement):P3-01-12

30.

Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873–1881. doi:10.1001/jama.2011.593 CrossRefPubMed

31.

Roy LD, Sahraei M, Schettini JL, Gruber HE, Besmer DM, Mukherjee P (2014) Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer 14:225. doi:10.1186/1471-2407-14-225 CrossRefPubMedPubMedCentral

32.

Owens P, Pickup MW, Novitskiy SV, Giltnane JM, Gorska AE, Hopkins CR, Hong CC, Moses HL (2014) Inhibition of BMP signaling suppresses metastasis in mammary cancer. Oncogene. doi:10.1038/onc.2014.189 PubMedPubMedCentral

33.

Semesiuk NI, Zhylchuk A, Bezdenezhnykh N, Lykhova A, Vorontsova AL, Zhylchuk VE, Kudryavets YI (2013) Disseminated tumor cells and enhanced level of some cytokines in bone marrow and peripheral blood of breast cancer patients as predictive factors of tumor progression. Exp Oncol 35(4):295–302PubMed

34.

Bendinelli P, Maroni P, Matteucci E, Luzzati A, Perrucchini G, Desiderio MA (2014) Microenvironmental stimuli affect Endothelin-1 signaling responsible for invasiveness and osteomimicry of bone metastasis from breast cancer. Biochim Biophys Acta 1843(4):815–826. doi:10.1016/j.bbamcr.2013.12.015 CrossRefPubMed

35.

Chen X, Lu J, Ji Y, Hong A, Xie Q (2014) Cytokines in osteoblast-conditioned medium promote the migration of breast cancer cells. Tumour Biol 35(1):791–798. doi:10.1007/s13277-013-1109-0 CrossRefPubMed

36.

Ren L, Wang X, Dong Z, Liu J, Zhang S (2013) Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway. Med Oncol 30(3):634. doi:10.1007/s12032-013-0634-4 CrossRefPubMed

37.

Nagahara M, Mimori K, Kataoka A, Ishii H, Tanaka F, Nakagawa T, Sato T, Ono S, Sugihara K, Mori M (2010) Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin Cancer Res 16(18):4625–4635. doi:10.1158/1078-0432.ccr-10-0349 CrossRefPubMed

38.

Uluckan O, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, Frazier WA, Weilbaecher KN (2009) CD47 regulates bone mass and tumor metastasis to bone. Cancer Res 69(7):3196–3204. doi:10.1158/0008-5472.can-08-3358 CrossRefPubMedPubMedCentral

39.

Na YR, Yoon YN, Son DI, Seok SH (2013) Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS ONE 8(5):e63451. doi:10.1371/journal.pone.0063451 CrossRefPubMedPubMedCentral

40.

Venmar KT, Carter KJ, Hwang DG, Dozier EA, Fingleton B (2014) IL4 receptor ILR4alpha regulates metastatic colonization by mammary tumors through multiple signaling pathways. Cancer Res 74(16):4329–4340. doi:10.1158/0008-5472.can-14-0093 CrossRefPubMedPubMedCentral

41.

Chappard D, Bouvard B, Basle MF, Legrand E, Audran M (2011) Bone metastasis: histological changes and pathophysiological mechanisms in osteolytic or osteosclerotic localizations: a review. Morphologie 95(309):65–75. doi:10.1016/j.morpho.2011.02.004 CrossRefPubMed

42.

Aldridge SE, Lennard TW, Williams JR, Birch MA (2005) Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br J Cancer 92(8):1531–1537. doi:10.1038/sj.bjc.6602417 CrossRefPubMedPubMedCentral

43.

Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, Jaattela M (2005) Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev 19(5):570–582. doi:10.1101/gad.305405 CrossRefPubMedPubMedCentral

44.

Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8(12):1197–1206CrossRefPubMed

45.

LaBarge MA (2013) Breaking the canon: indirect regulation of Wnt signaling in mammary stem cells by MMP3. Cell Stem Cell 13(3):259–260. doi:10.1016/j.stem.2013.08.008 CrossRefPubMed

46.

Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H (2007) The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomark Prev 16(6):1087–1097. doi:10.1158/1055-9965.epi-06-1008 CrossRef

47.

Wiesmann F, Veeck J, Galm O, Hartmann A, Esteller M, Knuchel R, Dahl E (2009) Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer. Breast Cancer Res 11(3):R34. doi:10.1186/bcr2319 CrossRefPubMedPubMedCentral

48.

Mu Y, Sundar R, Thakur N, Ekman M, Gudey SK, Yakymovych M, Hermansson A, Dimitriou H, Bengoechea-Alonso MT, Ericsson J, Heldin CH, Landstrom M (2011) TRAF6 ubiquitinates TGFbeta type I receptor to promote its cleavage and nuclear translocation in cancer. Nat Commun 2:330. doi:10.1038/ncomms1332 CrossRefPubMedPubMedCentral

49.

Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van’t Veer L, Hylton N (2012) Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN 6657. J Clin Oncol 30(26):3242–3249. doi:10.1200/jco.2011.39.2779 CrossRefPubMedPubMedCentral

50.

Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA (2006) Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107(2):289–298. doi:10.1002/cncr.21978 CrossRefPubMed

51.

Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295(14):1658–1667. doi:10.1001/jama.295.14.1658 CrossRefPubMedPubMedCentral

52.

Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu J, Hou K, Yang X, Liu Y, Qu X (2012) Receptor activator for nuclear factor kappa B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis. J Clin Pathol 65(1):36–40. doi:10.1136/jclinpath-2011-200312 CrossRefPubMed

53.

Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G (2011) Expression pattern of receptor activator of NF kappa B (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 226(3):780–784. doi:10.1002/jcp.22402 CrossRefPubMed

54.

Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8(2):98–101PubMed

55.

Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379(9810):39–46. doi:10.1016/s0140-6736(11)61226-9 CrossRefPubMed

56.

Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25(2):119–129. doi:10.1007/s10585-007-9127-1 CrossRefPubMed

57.

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139. doi:10.1200/jco.2010.29.7101 CrossRefPubMed

58.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082–3092. doi:10.1016/j.ejca.2012.08.002 CrossRefPubMed

59.

Grant M PG, Dubsky PC, Hubalek M, Greil R, Jakesz R et al (2015) The impact of adjuvant denosumab on disease-free survival: results from 3, 425 postmenopausal patients of the ABCSG-18 trial. San Antonio Breast Cancer Symposium. San Antonio, Texas. Abstract S2-02

60.

Study of Denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE). NCI Clinical Trial NCT01077154. https://clinicaltrials.gov/ct2/show/NCT01077154. Accessed 28 May 2017

Titel: Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657)
verfasst von: Neelima Vidula
Christina Yau
Jiali Li
Laura J. Esserman
Hope S. Rugo
Publikationsdatum: 02.06.2017
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4318-1

Springer Medizin

Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657)

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Breast cancer risk and clinical implications for germline PTEN mutation carriers

Unenhanced magnetic resonance screening using fused diffusion-weighted imaging and maximum-intensity projection in patients with a personal history of breast cancer: role of fused DWI for postoperative screening

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis

First international consensus conference on standardization of oncoplastic breast conserving surgery

Extensions of the Rosner-Colditz breast cancer prediction model to include older women and type-specific predicted risk

The Canadian National Breast Screening Studies are compromised and their results are unreliable. They should not factor into decisions about breast cancer screening

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie